About Proteus Digital Health
Armed with more than 450 issued patents and led by some of the brightest minds in technology, pharmaceuticals and healthcare, we’ve invented Digital Medicine, a new category of pharmaceuticals that measures medication treatment effectiveness, helps physicians improve clinical outcomes and patients reach health goals. Together, with leading health systems and pharmaceutical companies, we’re bringing this new digital solution to healthcare providers, thereby increasing access to better insight, optimized therapies and lower costs.
Meet our Executive Team
-
Andrew Thompson
Co-Founder, CEO -
George Savage, M.D.
Co-Founder, Chief Medical Officer -
Jeremy Frank
Senior Vice President, Digital Medicine -
Sean Handel
Senior Vice President Product -
Uneek Mehra
Chief Financial Officer -
David O'Reilly
Chief Platform Officer -
Olivia Ware
Senior Vice President, US Market and Franchise Development -
Mark Zdeblick, Ph.D.
Co-Founder, Chief Technologist
Our executive team and board of directors guide Proteus based on their depth of expertise across life sciences, consumer technology and capital markets.
Andrew Thompson
Co-Founder, CEO
Andrew Thompson is Co-Founder, President and Chief Executive Officer of Proteus Digital Health. His vision for Digital Medicines is focused on expanding global access to care, dramatically increasing the value delivered by drugs, and creating a more sustainable model for innovation in pharmaceuticals that leverages the power of silicon, software and mobile devices. Thompson is a World Economic Forum Advisor, and a member of the selection committee for the World Economic ForumTechnology Pioneers. He also serves on the California Governor’s Health IT Security Advisory Board.
Passionate about bringing digital innovation to education, he is Co-Founder and Board Member of Summit Schools, a leading Charter School organization with an acclaimed track record and unique digital platform, featured in the Davis Guggenheim movie “Waiting for Superman”. He works in digital humanities innovation as a Member of the Stanford University Libraries Board and with Cambridge University. He is a Co-Founder of Parker Library Online – a leading destination for digital medieval studies.
Thompson has been active as a venture capital investor and entrepreneur in Silicon Valley for 30 years, completing several Fortune 100 M&A transactions and IPOs, and is a named author on 51 issued patents. He holds master’s degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB).
George Savage, M.D.
Co-Founder, Chief Medical Officer
George Savage is Chief Medical Officer and Co-Founder of Proteus Digital Health, and formerly the company’s vice president of research and development. He sees Digital Medicine as an invaluable collaboration platform for patient and physician, integrating information about a patient’s response to therapy directly into everyday healthcare.
George is focused on developing the clinical and economic evidence needed to secure global regulatory approvals and spur widespread adoption of Proteus’s ingestible sensor platform. He serves on the board of the California Life Sciences Association, the Boston University College of Engineering advisory council, and in 2016 was elected a Fellow of the American Institute for Medical and Biological Engineering.
George holds a B.S. in Biomedical Engineering from Boston University, an M.D. from Tufts University School of Medicine, and an M.B.A. from Stanford University Graduate School of Business. He completed postgraduate training in surgery at the University of Massachusetts and is licensed to practice medicine in California. George has a successful 27-year track record of starting and developing technology-based healthcare companies in Silicon Valley.
Jeremy Frank
Senior Vice President, Digital Medicine
Dr. Jeremy Frank is Senior Vice President of Digital Medicine at Proteus Digital Health and is responsible for the formulation and development of digital medicines, as well as the technical operations, required by Proteus and its pharmaceutical partners.
Prior to his current role, Jeremy led all regulated product development efforts at Proteus (wearable sensors, ingestible sensors, medical software, and systems integration) and the launch of Proteus’ first commercial pilot, Helius, in the United Kingdom. Also, he was responsible for oversight of the qualification and scaling of the manufacturing operations of Proteus’ ingestible sensor.
Dr. Frank holds a Ph.D. in Mechanical Engineering from University of California, Berkeley, and a Bachelor’s degree in Mechanical Engineering from Stanford University.
Sean Handel
Senior Vice President Product
Sean Handel leads product management, design and software engineering at Proteus Digital Health. Most recently, Sean was Senior Vice President of Product at Swrve, a mobile engagement platform that helps major brands to engage their customers via their mobile apps. Previously, Sean was SVP Product Management and Marketing at Epocrates where he led product initiatives from an early stage through the company’s IPO and subsequent acquisition by Athenahealth. This included offerings for providers, health systems, health plans, and pharmaceutical companies. Epocrates became the number one brand in healthcare technology for physicians—at its peak, Epocrates was used by more than 50% of all physicians in the US and 1.4 million healthcare providers overall.
Sean holds Bachelor of Arts and Master of Science degrees in Computer Science from Northwestern University. He also advises technology startups in the healthcare technology and sports & fitness wearables areas.
Uneek Mehra
Chief Financial Officer
As Chief Financial Officer, Uneek is responsible for accounting, financial reporting, budgeting, business planning and forecasting. He is also responsible for the Facilities, IT and People teams. Prior to joining Proteus, Uneek had extensive experience in senior finance leadership roles with Novartis, IBM and Citibank. At Novartis, Uneek worked in roles with increasing responsibilities in the Corporate Finance, Commercial Finance, Corporate Business Development and Treasury departments across the US, Switzerland and China. He also served as CFO of two of the largest specialty Medicines Franchises within the Novartis US business.
Uneek has a MBA in Strategy and Leadership from IMD, Lausanne, Switzerland as well as a Masters in Finance and a Bachelors in Engineering from premier universities in India.
David O'Reilly
Chief Platform Officer
David O’Reilly is Chief Platform Officer of Proteus Digital Health and leads the company’s Digital Medicine development, manufacturing, corporate development and corporate strategy areas. Prior to joining Proteus, David spent over 15 years starting and building life sciences companies focused on novel platforms for drug discovery and personalized medicine. He was President of Catalyst Biosciences, Chief Business Officer and member of the founding management team at Iconix Biosciences, and Head of Corporate Development for ARIAD Pharmaceuticals (where he was also the general manager of a subsidiary company, ARIAD Gene Therapeutics). He began his career as a management consultant to healthcare and biotechnology companies at L.E.K. Consulting.
David is a graduate of Wesleyan University, where he was named the Gilbert Clee Scholar, and Harvard Business School, where he received an MBA with Distinction.
Olivia Ware
Senior Vice President, US Market and Franchise Development
Olivia Ware is a successful executive with over 20 years of experience in commercialization, pharmaceutical drug development and healthcare management. As SVP of US Market and Franchise Development, Olivia provides the strategy and guidance for global product launches and market assessments.
Most recently, Olivia worked as an independent consultant providing strategic support, management expertise and mentoring for companies across the biotech and pharmaceutical industries. Previously, Olivia served as Chief Commercial Officer at CytRX and held several senior leadership positions at Genentech. During her 13 years at Genentech, Olivia played key roles in the launch of several of the world’s largest revenue producing oncology drugs, including Rituxan®, Herceptin® and Avastin®.
Olivia has an MBA in Finance and Marketing, from the University of North Carolina at Chapel Hill and an A.B. from Davidson College.
Mark Zdeblick, Ph.D.
Co-Founder, Chief Technologist
Mark Zdeblick is Chief Technologist and Co-Founder of Proteus Digital Health, and leads the group innovating on our technology. Previously, Mark served as the Chief Technology Officer for the optical switch group at K2 Optronics and served as founder and Chief Technology Officer of Redwood Microsystems.
Mark holds a B.S. in Civil Engineering and a B.A. in Architecture, both from the University of Illinois, and an M.S. in Aeronautics and Astronautics and Ph.D. in Electrical Engineering from Stanford University.
Meet our Board of Directors
-
Jonathan Symonds, CBE
Chairman -
Shumeet Banerji, Ph.D.
Board Member -
Regina Benjamin, MD, MBA
Board Member -
Robert Epstein, M.D., M.S.
Board Member -
Frank Fischer
Board Member -
Alan J. Levy, Ph.D.
Board Member -
Myrtle Potter
Board Member -
Ryan Schwarz
Board Member -
Charles Songhurst
Board Member -
Joseph R. Swedish
Board Member -
Immanuel Thangaraj
Board Member
Our executive team and board of directors guide Proteus based on their depth of expertise across life sciences, consumer technology and capital markets
Jonathan Symonds, CBE
Chairman
Jon Symonds, CBE, is Chairman of HSBC Bank Plc, Chairman of the Supervisory Board of Innocoll AG and Non-Executive Director of Genomics England. He serves on the boards of Tala Energy, Feliz Pharmaceuticals, Aetion Inc., and Mesoblast.
Formerly, Symonds was Chief Financial Officer of Novartis, Partner and Managing Director of Goldman Sachs and Chief Financial Officer of AstraZeneca Plc.
Symonds has served on the Proteus Board of Directors since June of 2014 and now advises Proteus on strategy, financial management and corporate governance in his role as Chairman.
Shumeet Banerji, Ph.D.
Board Member
Shumeet Banerji is founder and partner of Condorcet, LP an investment and advisory firm. In 2013, Dr. Banerji retired from Booz & Company Inc. having served as its founding Chief Executive Officer.
Formerly, he held leadership roles at Booz, Allen & Hamilton in India, the U.K., Europe and globally. He serves on the Board of HP, Inc., Reliance Industries Limited, Proteus Digital Health, Inc., Felix Pharmaceuticals Private Limited, and Tala Energy Private Limited.
Dr. Banerji provides oversight on Proteus’ corporate strategy and operational performance, among other topics of critical importance.
Regina Benjamin, MD, MBA
Board Member
Dr. Regina Benjamin is the Founder and CEO of BayouClinic in Bayou La Batre, Alabama, and the NOLA.com/Times Picayune Endowed Chair of Public Health Sciences at Xavier University of Louisiana.
She was the 18th United States Surgeon General (2009 – 2013).
Dr. Benjamin serves on the boards of Kaiser Foundation Health Plan and Hospitals, the largest U.S. health managed care organization, and of Ascension, the world’s largest faith-based health system. She also serves on the boards of Diplomat, ConvaTec, CPSI, Next Level Health, and 98point6.
Robert Epstein, M.D., M.S.
Board Member
Dr. Robert Epstein is the cofounder and CEO of Epstein Health, LLC, a life science strategic consulting firm serving clients in the United States and Europe. Previously, Dr. Epstein served as president of the Medco-UBC Division and chief R&D officer of Medco Health Solutions, Inc.
Dr. Epstein is the former president of the International Society of Pharmacoeconomics and Outcomes Research, and currently serves on the board of directors of Illumina, Fate Therapeutics, Veracyte, and Mindstrong Health.
He has published more than 50 peer-reviewed medical articles and book chapters, and serves as a reviewer for several influential medical journals.
Frank Fischer
Board Member
Frank Fischer has more than 25 years of senior management experience in the medical device industry.
The president and CEO of the biomedical device company NeuroPace, he has served on the company’s board since 1998 and joined the company as its chief executive officer in January 2000.
Mr. Fischer continues to serve on the boards of several privately held medical device companies, in addition to serving on the board of trustees of Epilepsy Foundation of America, Rensselaer Polytechnic Institute, and Babson College.
Alan J. Levy, Ph.D.
Board Member
Dr. Alan Levy is a venture partner with Frazier Healthcare Partners and has over 30 years of senior management experience in the medical device industry.
Dr. Levy serves on the board of Intuitive Surgical, a publicly held company, in addition to Chrono Therapeutics, AbyRx, Signum Surgical, and the Center for Infectious Disease Research.
Myrtle Potter
Board Member
Myrtle Potter is founder and CEO of Myrtle Potter and Company. A best-selling author, Ms. Potter has dedicated three decades to serving the healthcare needs of millions of consumers.
She serves on the board of Rite Aid Corp., Liberty Mutual Insurance Group, and Insmed, Inc., and is on the University of Chicago Board of Trustees. Ms. Potter was president and chief operating officer of Genentech, president at Bristol-Myers Squibb and a vice president at Merck.
Ryan Schwarz
Board Member
Ryan Schwarz serves as managing director of NaviMed Capital and has over 30 years of investment and financial experience in healthcare. Previously, Mr. Schwarz led the healthcare investing practice for The Carlyle Group’s U.S. Venture & Growth Capital Group, specializing in medical devices, medical technology and healthcare information technology.
Mr. Schwarz currently serves on the boards of Lucent Health Solutions, Argos Health, and ORN Healthcare.
Charles Songhurst
Board Member
Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He runs an investment portfolio and the Songhurst Group which holds asset in a variety of private companies.
Mr. Songhurst serves on the boards of Rigetti, SafeGraph, and CodeFights. Previously, he ran corporate strategy for Microsoft and focused on partnering and M&A.
Joseph R. Swedish
Board Member
Joseph R. Swedish is Executive Chairman of Anthem Inc., a Fortune 50 company, and the nation’s leading health benefits provider.
Formerly, Swedish served as CEO for several major integrated healthcare delivery systems, including Trinity Health, Colorado’s Centura Health, and Hospital Corporation of America.
Swedish serves on numerous corporate and industry association boards, and joined the Proteus Board of Directors in February 2018. He received his bachelor’s degree from the University of North Carolina at Charlotte and his master’s degree in health administration from Duke University.
Immanuel Thangaraj
Board Member
Immanuel Thangaraj is a managing director at Essex Woodlands, a leading health care venture capital and growth equity company.
With more than 15 years of experience in operations and venture capital, he currently serves on the boards of Acura Pharmaceuticals, Kona Medical, Inc., and Serene LLC.
Work for a leader
that's transforming the industry.
We are Proteus Digital Health, the driving force behind an entirely new category of pharmaceuticals called Digital Medicine. Every day, our employees are blazing new trails at the intersection of pharmaceuticals, technology, software and healthcare. Our company is on the forefront of transformative change to the healthcare industry. We are searching for pioneers, problem-solvers and inquisitive minds to help realize our vision: to improve healthcare for everyone, everywhere. Do you want to work in a dynamic environment where you can grow personally as well as professionally? Then apply today to join the Proteus team.


difference
in the world
"We are developing a product that is changing people's lives."
Jeff Wiley, Head of Product Management
At Proteus Digital Health, we are developing leading-edge technology that will revolutionize how healthcare is delivered. What does that mean for our associates? They are playing an active role in the evolution of modern healthcare. Whether you are a software engineer, a data analyst or a pharmaceutical expert, you can help develop and deliver solutions that enhance the quality of care for everyone:
- Patients get back on track
- Physicians get deeper insight into patient health
- Healthcare systems can better measure, manage and improve the health of entire patient populations


for everyone everywhere
“We acknowledge hard work and celebrate success every chance we get.”
Priya Raval, Senior Designer, HFE and User Research.
Proteus Digital Health is a company like no other, offering the discipline of a healthcare leader and the mentality of a tech innovator. Every week, our associates are taking on challenges and solving problems. As a company on the leading edge, we’re searching for a unique type of employee — someone with an entrepreneurial mindset and a can-do spirit who enjoys working in a fast-paced environment. We offer:
- Personal development — there’s always an opportunity to learn and grow.
- Entrepreneurial spirit — as an industry pioneer, we are constantly paving new ground.
- Team mentality — we promote a culture of collaboration and teamwork.
- Dynamic working environment — every day is filled with new challenges and breakthroughs.


Teamwork
Leadership
Upcoming Events
-
Spotlight on Global Access to Health
Time: January 22 at 9:45 a.m.
Location: Congress Centre, Jakobshorn, Davos, Switzerland
Speaker: Andrew Thompson, Proteus Digital Health Chief Executive Officer and Co-FounderExperts believe that emerging digital platforms and ecosystems could account for more than $60 trillion in revenue by 2025 (or more than 30% of global corporate revenue), and yet only 3% of established companies have adopted an active platform strategy. Mr. Thompson and leaders from financial and academic institutions come together to address “Theory of the Firm in a World of Digital Ecoystems.”
-
Spotlight on Global Access to Health
Time: January 22 at 8:05 p.m.
Location: Polish House, Davos, Switzerland
Speaker: Andrew Thompson, Proteus Digital Health Chief Executive Officer and Co-FounderMr. Thompson will provide a keynote address on the applications of digital medicines today at the Financial Times-PZU “Spotlight on Global Access to Health,” followed by a 45-minute Fireside Chat entitled “Building Future-Forward Healthcare for All.”
-
Health at the Crossroads: Seven Drivers of Change
Time: January 23 at 7:00 a.m.
Location: A.T. Kearney Glass House, Davos, Switzerland
Speaker: Andrew Thompson, Proteus Digital Health Chief Executive Officer and Co-FounderMr. Thompson and fellow healthcare executives will debate the future of health in a panel entitled “Health at the Crossroads: Seven Drivers of Change,” sponsored by A.T. Kearney.
-
Bridging Science with Society
Time: January 25 at 9:00 a.m.
Location: Swiss Alpine High School Auditorium, Davos, Switzerland
Speaker: Andrew Thompson, Proteus Digital Health Chief Executive Officer and Co-FounderMr. Thompson will join state and religious leaders in the Open Forum “Bridging Science with Society,” scheduled to begin at 9:00 a.m. CET on Friday, January 25, 2019 at the Swiss Alpine High School Auditorium. This session will be livestreamed on TopLink and the Forum website.
Press Releases
-
January 21, 2019
Proteus Digital Health® Founder to Present at World Economic Forum in Davos
REDWOOD CITY, Calif., Jan. 21, 2019 – Proteus Digital Health® announced today that Andrew Thompson, its President, Chief Executive Officer and Co-Founder, will present on the progress of Proteus’ digital medicines to improve patient treatment ...
Read moreRead more -
January 17, 2019
Proteus Digital Health® Launches Digital Oncology Medicines to Improve Patient Outcomes
Proteus, Fairview Health Services, and University of Minnesota Health are First to Provide Digital Medicines to Cancer Patients January 17, 2019 – REDWOOD CITY, Calif. and MINNEAPOLIS, Minn. – Proteus Digital Health®, Inc., Fairview Health ...
Read moreRead more -
January 4, 2019
Proteus Digital Health to Present at the 37th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 4, 2019 – Proteus Digital Health announced today that Andy Thompson, Founder and Chief Executive Officer, will present an overview and update on Proteus Digital Health and digital medicines at the 37th Annual J.P. ...
Read moreRead more
-
October 11, 2018
Otsuka and Proteus Digital Health Announce Expanded Collaboration Agreement to Advance Digital Medicines For Mental Health
Princeton, New Jersey and Redwood City, Calif. – October 11, 2018 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announce the signing of an expanded global collaboration agreement that will strengthen the ...
Read moreRead more -
August 14, 2018
Digital Medicines Value-Based Contract Focused on Improving Patient Outcomes Established Between Desert Oasis Healthcare and Proteus Digital Health®
August 14, 2018 –PALM SPRINGS, Calif. and REDWOOD CITY, Calif. – Desert Oasis Healthcare (DOHC) and Proteus Digital Health®, Inc. announced today a multi-year collaboration established with a value-based contract. Enabled by Digital Medicines, ...
Read moreRead more -
April 25, 2018
Proteus Digital Health® Announces Digital Medicines Pipeline Development and Expansion into Oncology
Proteus Digital Health®, Inc. today announced that together with its collaborators, the company has developed a pipeline of 31 digital medicines for mental health, cardiovascular and metabolic conditions, infectious diseases, and oncology. ...
Read moreRead more -
February 13, 2018
Executive Chairman of Anthem Inc., Joseph Swedish, Joins the Board of Proteus Digital Health™
Proteus Digital Health™ announced today that Joseph Swedish, the Executive Chairman of Anthem Inc., (NYSE ANTM) has joined its Board of Directors. Anthem, Inc. is the nation’s leading health benefits provider. Mr. Swedish was named ...
Read moreRead more
-
November 14, 2017
Otsuka and Proteus® Announce the First U.S. FDA Approval of a Digital Medicine System: Abilify MyCite® (aripiprazole tablets with sensor)
ABILIFY MYCITE (aripiprazole tablets with sensor) is a drug-device combination product comprised of Otsuka’s oral aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor. The ABILIFY MYCITE System includes: ABILIFY MYCITE, the ...
Read moreRead more -
September 5, 2017
Former U. S. Surgeon General Dr. Regina Benjamin Joins the Board of Proteus Digital Health™
Redwood City, Calif. — September 5, 2017 – Proteus Digital Health™ today announced the addition of Regina Benjamin, MD, MBA, the 18th United States Surgeon General, to its Board of Directors. As America’s Doctor from July 2009 to 2013, Dr. ...
Read moreRead more -
August 23, 2017
Senior Novartis Executive Joins Proteus Digital Health™ as Chief Financial Officer
Redwood City, Calif. — August 23, 2017 – Proteus Digital Health™ announced today that Uneek Mehra has joined the company as Chief Financial Officer. Mr. Mehra has more than twenty years of global finance experience and was previously a senior ...
Read moreRead more -
May 23, 2017
Otsuka and Proteus Digital Health® Resubmit Application to FDA for First Digital Medicine
Potential new Digital Medicine consists of Otsuka’s ABILIFY® (aripiprazole) embedded with the Proteus ingestible sensor, for serious mental illness Drug/ice product digitally records medication ingestion and, with patient consent, shares ...
Read moreRead more
-
April 26, 2016
FDA Issues Complete Response Letter for Digital Medicine New Drug Application
TOKYO, JAPAN and REDWOOD SHORES, CALIF. – April 26, 2016 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response ...
Read moreRead more -
April 15, 2016
Proteus Digital Health Raises Additional $50 Million in Equity Financing
REDWOOD CITY, CALIF. – April 15, 2016 – Leading Digital Medicine company Proteus Digital Health announced today it has secured $50 million in Series H financing. This investment further strengthens the company’s balance sheet and provides ...
Read moreRead more -
April 4, 2016
Proteus Digital Health Presents Interim Results at ACC From a Randomized Controlled Clinical Study of Proteus Discover
Digital Medicines Study Demonstrates Patients Benefit from Feedback on Medication Adherence and Behavior Patterns APRIL 04, 2016 – CHICAGO, IL – Proteus Digital Health presented interim results from a randomized controlled study of Proteus ...
Read moreRead more -
January 27, 2016
The next level of on-demand expert medical care is here: USC Center for Body Computing announces its Virtual Care Clinic (VCC) in collaboration with eight strategic partners for an ‘anytime, anywhere’ disruptive health care model to deliver borderless health care
Innovative digital health solution uses mobile apps, wearable sensors, virtual human health care providers, augmented and virtual reality (AR/VR), data collection, analytics and artificial intelligence using digital communication tools to ...
Read moreRead more -
January 11, 2016
Barton Health First to Implement Proteus Digital Health’s Innovative Solution for Patients with Chronic Conditions
JANUARY 11, 2016 – REDWOOD CITY, and SOUTH LAKE TAHOE, CA—Barton Health is the first health system to implement Proteus Discover, a Digital Medicine offering that activates patients and enables rapid assessment and personalized treatment ...
Read moreRead more
-
November 17, 2015
Proteus Digital Health Announces New Chairman of the Board and Chief Commercial Officer
Leading Digital Medicines Company Strengthens Customer and Corporate Governance Capabilities to Advance Commercialization NOVEMBER 17, 2015, REDWOOD CITY, CA—Proteus Digital Health™ announced three executive appointments in order to propel the ...
Read moreRead more -
September 10, 2015
U.S. FDA Accepts First Digital Medicine New Drug Application for Otsuka and Proteus Digital Health
The first Digital Medicine, a drug/ice product, combines Otsuka’s ABILIFY® (aripiprazole) for serious mental illness, embedded with the Proteus® ingestible sensor in a single tablet to digitally record ingestion and, with patient consent, share ...
Read moreRead more -
July 2, 2015
First Medical Device Cleared by FDA With Adherence Claim
REDWOOD SHORES, CALIF. Proteus Digital Health, Inc. today announced that the FDA has expanded the Indications for Use statement for the latest generation of its Ingestible Sensor technology, enabling the device to be used as an aid in the ...
Read moreRead more -
January 12, 2015
Oracle and Proteus Integrate Proteus Digital Health Feedback System with Oracle Health Sciences InForm to Help Increase Clinical Trial Accuracy
Oracle Health Sciences InForm electronic data capture platform utilizes Proteus solution, enabling greater accuracy in measuring medication adherence during clinical trials REDWOOD SHORES News Summary Highly engaged patients that consistently ...
Read moreRead more
-
July 29, 2014
Proteus Digital Health™ Continues to Build Momentum, Most Recent Round of Funding Reaches over $172MM
REDWOOD CITY, CA — Proteus Digital Health, Inc., the leading digital medicines company, today announced that it has completed a second closing of its Series G financing, raising over $172 million and adding additional respected institutional ...
Read moreRead more -
July 28, 2014
Proteus Digital Health Prevails in Trademark Infringement Case
REDWOOD CITY, Calif., (August 1, 2014) -– Proteus® Digital Health, a leading digital medicines company, today announced that it has entered into an agreement settling its claims against Texas-based Proteus Biomedical LLC for trademark ...
Read moreRead more -
June 2, 2014
Proteus Digital Health™ Raises $120 million, Strengthens Financial Management and Governance Expertise through Key Executive Appointments
Steve Fieler joins as Chief Financial Officer, completing the company’s executive team Jonathan Symonds, former CFO of Novartis AG, appointed to Board of Directors REDWOOD CITY, CA—Leading digital medicines company Proteus Digital Health™ raised ...
Read moreRead more -
April 16, 2014
Proteus Digital Health Grows Leadership Team and Board of Directors with Former Executives from Novartis, Microsoft and Egreetings Network
REDWOOD CITY, Calif. — Proteus Digital Health (TM), a leading digital medicines company, today announced the expansion of the company’s executive team and board of directors with the addition of three industry leaders across consumer technology ...
Read moreRead more -
March 10, 2014
Proteus Digital Health™, NHS England and UK Trade & Investment to Bring Transformative Digital Health Technology to the UK
LONDON, ENGLAND— Leading digital medicines company Proteus Digital Health™ is partnering with Eastern Academic Health Science Network (EAHSN), The Northern Health Science Alliance (NHSA) and Oxford University, Oxford University Hospitals NHS ...
Read moreRead more
-
May 1, 2013
Oracle Invests in Proteus Digital Health and its FDA-Approved Ingestible Sensor Platform
Digital Health Feedback System Will Allow Oracle’s Clinical Trial Applications Customers Exclusive Access to Real-time Data on Therapeutic Use to Dramatically Improve Clinical Trial Efficiency Redwood Shores, CA – May 1, 2013 News Facts Oracle ...
Read moreRead more -
May 1, 2013
Proteus Digital Health Completes $62.5 Million Financing
Proceeds to Advance Development of Digital Medicine Products Redwood City, Calif. – May 1, 2013 Proteus Digital Health, Inc announced today that the company has completed a second closing of its Series F financing, raising $62.5 million in ...
Read moreRead more -
January 7, 2013
Proteus Digital Health Expands Commercial Team and Board of Directors to Drive Commercial Growth
REDWOOD CITY, Calif. – January 7, 2013 Proteus Digital Health Inc. announced today the expansion of the company’s executive team and board of directors with the addition of three healthcare leaders to drive its commercial strategy as the company ...
Read moreRead more
-
July 30, 2012
Proteus Digital Health Announces FDA Clearance of Ingestible Sensor
REDWOOD CITY, Calif. – July 30, 2012 – Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its ingestible sensor for marketing as a medical device. The ingestible sensor (formally referred to ...
Read moreRead more -
July 5, 2012
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products
REDWOOD CITY, CA, and TOKYO, JAPAN, July 5, 2012 – Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. announced they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new ...
Read moreRead more -
January 31, 2012
Proteus Announces Issuance of U.S. Patent for Digital Health Communications
Proteus Biomedical Inc., a pioneer in digital health, announced today that the United States Patent Office will award U.S. Patent Number 8114021 to Proteus. The patent, entitled “Body Associated Receiver and Method,” is directed to the Proteus ...
Read moreRead more -
January 13, 2012
Lloydspharmacy partners with Proteus Biomedical to launch innovative digital health product
UK community pharmacy chain Lloydspharmacy and US company Proteus Biomedical, Inc., a pioneer in digital health, have today announced an exclusive strategic collaboration to commercialize and launch Helius™, a digital health product focused on ...
Read moreRead more
-
September 15, 2011
Chris Brinsmead Appointed Chairman of Proteus Biomedical Europe
2012 UK Launch of First Commercial Product Planned Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that Chris Brinsmead has joined the company as Chairman, Proteus Biomedical Europe. Brinsmead has over 30 years of ...
Read moreRead more -
July 14, 2011
Proteus Announces Issuance of U.S. Patent for Ingestible Digital Devices
Technology to Become a Foundation for mHealth Products and Services Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that the United States Patent Office awarded U.S. Patent Number 7,978,064 to Proteus. The patent, ...
Read moreRead more -
June 7, 2011
Avery Dennison Medical Solutions and Proteus Biomedical Launch Partnership
Development, License and Manufacturing Agreements Focus on Wearable Sensor Technology Avery Dennison Medical Solutions, a division of Avery Dennison Corporation (NYSE: AVY) and a global leader in pressure-sensitive adhesive technologies for ...
Read moreRead more
-
August 13, 2010
Proteus Biomedical Announces European CE Mark Approval of Ingestible Sensor and Monitor System
Company Also Announces Creation of User Experience Group with Former IDEO Leader Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that it has received CE Mark approval to market its ingestible sensor and personal ...
Read moreRead more -
April 21, 2010
Proteus Announces FDA Clearance of Wireless Personal Health Monitor
Company Also Completes Financing with Leading Medical Device, Pharmaceutical and Semiconductor Companies as Investors Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that it has received 510(k) clearance from the US ...
Read moreRead more -
January 12, 2010
Proteus Biomedical Announces License and Collaboration Agreement for Sensor-Based Pharmaceuticals
Proteus Biomedical Inc., a pioneer in intelligent medicine, entered into an exclusive worldwide license and collaboration agreement with Novartis to develop and commercialize pharmaceutical products that incorporate Proteus’ novel sensor-based ...
Read moreRead more
-
December 4, 2008
Proteus Biomedical Honored by World Economic Forum
Technology Pioneer Award Recognizes Potential of Intelligent Medicine to Improve Business and Society Redwood City, Calif. – Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that the company has been selected a 2009 ...
Read moreRead more -
October 15, 2008
Proteus Biomedical Raises $32 Million in Series D Funding
Proceeds to Advance Development of Intelligent Medicine Products Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that the company has raised $32 million in a series D equity financing. New corporate investors ...
Read moreRead more -
April 24, 2008
Proteus Biomedical Initiates Clinical Study of Novel Technology for Heart Failure
Study To Assess Feasibility of First Application of Company’s Proprietary Platform Technology to Improve Myocardial Efficiency Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today the initiation of the RETIME 2.0 ...
Read moreRead more -
January 7, 2008
Proteus Biomedical Announces Appointment of Independent Directors
Accelerates Expansion of Pharmaceutical, Hospital Businesses Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that Ms. Ginger Graham and Ms. Kathy Murray have been appointed to serve on its divisional Boards of ...
Read moreRead more
Press Office
For product images, video footage and interview requests, please contact the Proteus Press Office. Media requests only.
Phone Press. +1.650.637.6225
press@proteus.com
investor@proteus.com
Our Partners
We have engaged license agreements with strategic partners to build our patented ingestible-sensor technology into new Digital Medicine offerings.
Otsuka
Otsuka and Proteus have combined Otsuka’s ABILIFY® (aripiprazole) with the FDA-cleared Proteus® ingestible sensor, embedding the sensor in single tablets at point of manufacture. The FDA granted its first approval of a Digital Medicine, ABILIFY MYCITE® (aripiprazole tablets with sensor), on November 13, 2017. ABILIFY MYCITE® is a drug -device combination product of Otsuka’s aripiprazole, an atypical antipsychotic, embedded with Proteus’ ingestible sensor that communicates with Proteus’ wearable sensor patch, and a smartphone application. The product measures ingestion of ABILIFY MYCITE® and patient activity, rest and mood. Otsuka’s first Digital Medicine provides an objective measure of medication-taking patterns of ABILIFY MYCITE® to help enhance collaboration with healthcare providers, who treat patients with certain serious mental illnesses.
Novartis
Proteus has had a strategic partnership with Novartis since 2009.